Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
|Videos|November 27, 2020
Restricted interview questions persist in urology match process
Author(s)Urology Times staff
Urology residency program applicants continue to face interview questions on restricted topics such as plans for having children.
Advertisement
In this interview, Stephanie J. Kielb, MD, discusses the recent Urology Practice study, The impact of stricter guidelines on post-interview contact, restricted interview topics and differences by gender in the urology match, for which she served as senior author. Kielb is chief of reconstruction and neurourology and professor of urology, medical education, and obstetrics and gynecology at Northwestern University Feinberg School of Medicine, Chicago.
Advertisement
Related to this article
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5